1. Home
  2. GANX vs ISPO Comparison

GANX vs ISPO Comparison

Compare GANX & ISPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GANX
  • ISPO
  • Stock Information
  • Founded
  • GANX 2017
  • ISPO 2010
  • Country
  • GANX United States
  • ISPO United States
  • Employees
  • GANX N/A
  • ISPO N/A
  • Industry
  • GANX Biotechnology: Pharmaceutical Preparations
  • ISPO Blank Checks
  • Sector
  • GANX Health Care
  • ISPO Finance
  • Exchange
  • GANX Nasdaq
  • ISPO Nasdaq
  • Market Cap
  • GANX 45.8M
  • ISPO 53.5M
  • IPO Year
  • GANX 2021
  • ISPO N/A
  • Fundamental
  • Price
  • GANX $1.80
  • ISPO $3.52
  • Analyst Decision
  • GANX Strong Buy
  • ISPO
  • Analyst Count
  • GANX 6
  • ISPO 0
  • Target Price
  • GANX $8.33
  • ISPO N/A
  • AVG Volume (30 Days)
  • GANX 262.8K
  • ISPO 23.8K
  • Earning Date
  • GANX 05-13-2025
  • ISPO 05-06-2025
  • Dividend Yield
  • GANX N/A
  • ISPO N/A
  • EPS Growth
  • GANX N/A
  • ISPO N/A
  • EPS
  • GANX N/A
  • ISPO N/A
  • Revenue
  • GANX N/A
  • ISPO $279,855,000.00
  • Revenue This Year
  • GANX N/A
  • ISPO N/A
  • Revenue Next Year
  • GANX N/A
  • ISPO $148.70
  • P/E Ratio
  • GANX N/A
  • ISPO N/A
  • Revenue Growth
  • GANX N/A
  • ISPO N/A
  • 52 Week Low
  • GANX $0.89
  • ISPO $3.11
  • 52 Week High
  • GANX $3.65
  • ISPO $9.31
  • Technical
  • Relative Strength Index (RSI)
  • GANX 46.13
  • ISPO 36.23
  • Support Level
  • GANX $1.64
  • ISPO $3.36
  • Resistance Level
  • GANX $1.80
  • ISPO $4.04
  • Average True Range (ATR)
  • GANX 0.18
  • ISPO 0.32
  • MACD
  • GANX 0.01
  • ISPO -0.04
  • Stochastic Oscillator
  • GANX 62.75
  • ISPO 13.47

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

About ISPO Inspirato Incorporated

Inspirato Inc is a luxury travel subscription luxury travel company that provides exclusive access to a managed and controlled portfolio of curated vacation options, delivered through a model designed to ensure the service, certainty, and value that discerning customers demand. The Inspirato portfolio includes branded luxury vacation homes, accommodations at five-star hotel and resort partners, and custom travel experiences. It has a geographic location in the United States and Outside the United States. It generates the majority of its revenue from the United States.

Share on Social Networks: